# CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma

> **NCT01740401** · PHASE2 · TERMINATED · sponsor: **Icahn School of Medicine at Mount Sinai** · enrollment: 10 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT01740401
- **Lead sponsor:** Icahn School of Medicine at Mount Sinai
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10
- **Primary completion:** 2013-12
- **Final completion:** 2014-12
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Primary Endpoint not met
- **Last updated:** 2017-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01740401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01740401, "CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01740401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*